ea0090p795 | Thyroid | ECE2023
Bestepe Nagihan
, Aydogmus Yasar
, Balsak Belma Tural
, Hafizoglu Emre
, Solmaz Kubra
, Topaloglu Oya
, Ersoy Reyhan
, Cakir Bekir
Introduction: Immune checkpoint inhibitors are relatively new and promising treatments for a variety of solid tumors. Nivolumab is an anti-cancer monoclonal antibody that inhibits anti-programmed death-1 (PD1) and modulates T-cell response. It has been shown to significantly improve survival in many types of cancer, but clinical studies have also reported an increased risk of developing immune-related adverse events. In particular, immune-related adverse events may be related ...